Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT06345521 for Heart Failure, Congenital, End-stage Heart Failure is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Etablishment of Follow-up System and End-Stage Heart Registration Platform for Pediatric Heart Failure 100 Pediatric
Clinical Trial NCT06345521 is an observational study for Heart Failure, Congenital, End-stage Heart Failure that is recruiting. It started on 1 January 2022 with plans to enroll 100 participants. Led by China National Center for Cardiovascular Diseases, it is expected to complete by 31 December 2024. The latest data from ClinicalTrials.gov was last updated on 28 May 2024.
Brief Summary
Establish a follow-up management system for pediatric heart failure and a registration platform for end-stage heart failure
Official Title
A Comprehensive Research of Pediatric Heart Failure-- Etablishment of Follow-up System and End-Stage Heart Registration Platform for Pediatric Heart Failure
Conditions
Heart FailureCongenitalEnd-stage Heart FailureOther Study IDs
- 2022-1-4032-3
NCT ID Number
Start Date (Actual)
2022-01-01
Last Update Posted
2024-05-28
Completion Date (Estimated)
2024-12-31
Enrollment (Estimated)
100
Study Type
Observational
Status
Recruiting
Keywords
Congenital Heart Failure
Registry
End-stage Heart Failure
Registry
End-stage Heart Failure
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
End-Stage Heart Failure Group Children with end-stage heart failure | No intervention No intervention |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
the recurrence rate of heart failure | During follow-up visits, echocardiographic examination is conducted to measure the left ventricular function. If LVEF falls under 55%, it is recorded as a recurrence. | 6 months |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
NT-proBNP level | The trend in NT-proBNP levels. | 6 months |
Incidence rate of drug adverse reactions | The incidence of abnormalities in complete blood count, electrolytes, liver and kidney function, and cardiac enzymes. | 6 months |
Readmission rate for heart failure | During follow-up visits, readmission for heart failure will be recorded. | 6 months |
Participation Assistant
Eligibility Criteria
Eligible Ages
Child
Eligible Sexes
All
- Patients younger than 14 years of age
- refractory heart failure
-
China National Center for Cardiovascular Diseases- Peking University First Hospital
- Beijing Children's Hospital
Study Central Contact
Contact: Kai Ma, PhD, +86 15901428497, [email protected]
Contact: Zheng Dou, PhD, +86 18810673618, [email protected]
1 Study Locations in 1 Countries
Fuwai hospital, Beijing, China
Shoujun Li, MD, Contact, +86 13501071589, [email protected]
Recruiting